Have you ever wondered how your diet affects your liver? It turns out that what you eat could play a significant role in the development of non-alcoholic fatty liver disease, a condition that can lead to serious health issues. This disease is tricky because it often shows no symptoms until it's advanced, making it hard to treat. A recent review of 18 studies involving over 262,000 people found a strong link between a high Dietary Inflammatory Index (DII)—which measures how much your diet may promote inflammation—and the risk of developing fatty liver disease. Specifically, people with a higher DII were more likely to develop not just fatty liver but also fibrosis, which is the scarring of the liver. For patients, this means that making healthier dietary choices could potentially lower the risk of liver problems. However, it's important to note that while the findings are significant, they don't prove cause and effect. More research is needed to fully understand this relationship. So, if you're concerned about your liver health, consider talking to your healthcare provider about how diet can play a role.
Could Your Diet Be Fueling Fatty Liver Disease?
Plain Language Summary
What this means for you:
Eating an anti-inflammatory diet may help protect your liver from serious disease. What this means for you:
Eating an anti-inflammatory diet may help protect your liver from serious disease. View Original Abstract ↓
BACKGROUND: The Dietary Inflammatory Index (DII) is a literature-based tool designed to predict inflammation. Previous studies suggest a potential association between the DII and non-alcoholic fatty liver disease (NAFLD). However, the relationship between the DII and both the incidence and progression of NAFLD remains unclear.
METHODS: Systematic literature searches were conducted in PubMed, Web of Science, Embase, Scopus, and the Cochrane Library up to July 2025. A random-effects model was applied, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses were performed to explore the sources of heterogeneity, while Egger's test was used to assess publication bias. Review Manager 5.4 and STATA 15.0 were employed for statistical analysis.
RESULTS: Eighteen studies involving 262,468 participants were included. The data indicated a significant association between the DII and NAFLD (OR = 1.33, 95% CI: 1.23-1.44; P < 0.00001) and between the DII and fibrosis (OR = 1.36, 95% CI: 1.20-1.54; P < 0.00001). Subgroup analysis identified geographic region and diagnostic criteria as sources of heterogeneity. Egger's test revealed publication bias for NAFLD.
CONCLUSION: A high DII was associated with an increased risk of NAFLD and an increased risk of progression to fibrosis.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD42025632168.